215 FIRST STREET, CAMBRIDGE, MA
Sarepta Therapeutics Approves 2026 Equity Incentive Plan at Annual Meeting
Announces First Quarter 2026 Financial Results and Recent Corporate Developments
Annual Report to Security Holders
Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments
CEO Departure - Douglas Ingram to Retire by End of 2026
Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
Sarepta Therapeutics Enters $291.4M Exchange Agreement for Convertible Notes
Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027
Q1
FY 2025
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
S-8 POS